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Background: Metabolic syndrome (MBS) has been reported as a frequent comorbidity 
in   psoriatic patients. The main pathogenesis is considered to be inflammation in this asso-
ciation. MBS has been investigated in eating disorders as well. While psoriasis has some 
psychiatric comorbidities, the link between psoriasis, MBS, and eating disorders (EDs) 
is unknown.
Methods: The study was designed as a cross-sectional, randomized, and controlled trial. A total 
of 100 patients with psoriasis were included in the study. Sociodemographic data, clinical sub-
type of psoriasis, Psoriasis Area and Severity Index (PASI) scores, and associated diseases were 
registered for each patient. The criteria for diagnosis of MBS developed by the International 
Diabetes Foundation (IDF) was used. These are central obesity (waist circumference $94 cm 
in men or $80 cm in women), plus two of the following: elevated triglycerides ($150 mg/dL), 
reduced high-desity lipoprotein cholesterol (.40 mg/dL for men; .50 mg/dL for women), 
elevated blood pressure ($130 mmHg systolic or $85 mmHg diastolic), and elevated fasting 
blood glucose ($100 mg/dL). Additionally, the Eating Attitude Test (EAT), Beck Depression 
Inventory (BDI), and Beck Anxiety Inventory (BAI), and psychiatric interview were performed 
for all patients.
Results: There were 45 female and 55 male patients, aged between 18 and 85 years old (median 
41.12 ± 16.01). MBS was present in 31% of the patients with psoriasis. There was no correlation 
between the severity of psoriasis and MBS. EAT scores were $30 in 7/100 patients. Four out 
of 31 patients with MBS (12.9%) had ED and 3/69 patients were without MBS (4.3%). Mean 
ED scores were compared statistically and the difference was significant (EAT = 17.9 ± 9.558 
and 11.5 ± 7.204, P , 0.001).
Conclusion: Defining risk factors leading to comorbidities is important in psoriasis. EDs 
seem to have an impact on the development of MBS in psoriasis. Establishment and treat-
ment of EDs in patients with psoriasis may prevent the onset of MBS and other comorbidities 
due to MBS.
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Introduction
Psoriasis is a chronic inflammatory skin disease. Variable immunological and inflam-
matory processes play a role in pathogenesis and also contribute to occurrence of 
comorbidities. While the more common concomitant disorders are psoriatic arthritis 
and depression/anxiety, research papers of comorbidities due to metabolic disregula-
tion and resultant metabolic syndrome (MBS) gradually increase.1–8 MBS is particu-
larly important, because it includes a cluster of risk factors such as central obesity, 
hypertension, abnormal glucose intolerance, and dyslipidemia, all of which are strong Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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predictors of cardiovascular disease, diabetes mellitus, and 
stroke.9–11 All these comorbidities are complex and are sup-
posed to share common pathogenetic pathways and cytokine 
profiles with psoriasis. Moreover, it is also important to be 
aware of some predisposing factors, such as sedentary life 
style, smoking, and alcoholism, which have been previously 
considered to be facilitating factors for the development of 
MBS in patients with psoriasis.12
Eating disorders (EDs) are characterized by clinically 
significant disturbances in eating behavior. They are often 
accompanied by another psychiatric disorder such as depres-
sion and anxiety. Particularly, binge-eating disorder (BED) 
may be associated with obesity and MBS.12,13 Hence, it is logi-
cal to consider that EDs are psychogenic cofactors which may 
contribute to the development of MBS in psoriatic patients 
who are also prone to various psychiatric comorbidites; for 
example, depression and anxiety.14–16
While a few studies demonstrate a link between MBS and 
EDs,17–19 there are also some studies implicating a relation-
ship between EDs and anxiety.20–22 If there is a relationship 
between EDs and psoriasis, diagnosing any ED would be use-
ful for suggesting a change in eating behavior of a psoriatic 
patient with MBS and thus improve resultant MBS.
Materials and methods
The study was designed as a cross-sectional, randomized, 
and controlled trial. A total of 100 patients with pso-
riasis (55 males, 45 females, age range 18–85, mean age 
41.12 ± 16.01) were included in the study. Sociodemographi-
cal data including sex, age, marital status and educational 
status, clinical subtype of psoriasis, psoriasis area severity 
index (PASI) scores, and other systemic diseases were reg-
istered for each patient. Additionally, Eating attitudes Test 
(EAT), Beck Depression Inventory (BDI), and Beck Anxiety 
Inventory (BAI) were performed on all patients.
EAT-26 is a widely used self-report measure of EDs, 
and although it was developed by Garner and Garfinkel 
in 197923 to measure symptoms of anorexia nervosa (AN), 
it has been used in nonclinical samples as a general screen-
ing measure for disordered eating attitudes. EAT-26 is based 
on EAT-40 and was adapted to Turkish by Erol and Savasir 
in 1989.24 Total scores on EAT-26 are derived as a sum of 
the composite items, ranging from 0 to 53, with a score of 
20 used as the cutoff.24 The Turkish version of EAT consists 
of 40 questions, the answers to which are evaluated with a 
six-point Likert scale, from “always” to “never.” The resulting 
scores range between 0 and 120 points, and individuals 
scoring $30 points are considered as at high risk of EDs.24 
The Turkish versions of BDI and BAI, reliability and valid-
ity studies of which had been previously performed in the 
Turkish population, were used.25–28
All patients were evaluated for the presence of MBS. 
The criteria developed by the International Diabetes 
  Foundation for diagnosis of MBS was used. These crite-
ria are central obesity (waist circumference $94 cm in 
men or $80 cm in women), plus two of the following: 
  triglycerides $150 mg/dL; high-desity lipoprotein choles-
terol ,40 mg/dL for men or ,50 mg/dL for women; blood 
pressure $130 mmHg systolic or $85 mmHg diastolic; 
and fasting blood glucose $100 mg/dL. Two study groups 
were formed according to these criteria. Group 1 con-
sisted of the patients who met MBS criteria, and Group 2 
consisted of the patients who did not meet MBS criteria. 
These two groups were compared statistically in terms 
of sociodemographical factors and the presence of MBS, 
EDs, depression, and anxiety. The patients who had an ED 
according to EAT were also evaluated by a psychiatrist, 
and the ED was confirmed by psychiatric examination and 
Diagnostics and Statistical Manual of Mental Disorders, 
4th edition criteria.29
Patients who were found to have an ED were assessed 
according to EAT, and a psychiatric interview was done by 
a psychiatrist. The patients were classified as having AN, 
bulimia nervosa (BN), BED, or an ED not otherwise speci-
fied (ED-NOS). Independent samples t-test, Mann–Whitney 
U-test, chi-square test, Fisher’s exact test, and SPSS Statistics 
11.5 (IBM Corporation, Somers, NY) software for Windows® 
were used for statistical assessments. P , 0.05 was consid-
ered statistically significant.
Results
Group 1 consisted of 31 patients with MBS (31%, mean age 
48.5 ± 13.4), and Group 2 consisted of 69 patients (69%, mean 
age 37.7 ± 16.0). When the two groups were compared, all 
parameters including sex, marital status, educational status, 
disease duration, type of psoriasis according to onset age 
(type I and type 2), and disease severity determined by PASI 
values except for age were statistically insignificant (Table 1). 
EAT scores were $30 in 7 out of 100 patients. Four out of 31 
patients with MBS (12.9%) and 3 out of 69 patients without 
MBS (4.3%) had an ED. However, statistical evaluation was 
impossible because of low numbers of patients; therefore, 
mean ED scores were evaluated and a statistically significant 
difference was found (EAT = 17.9 ± 9.558 and 11.5 ± 7.204, 
P , 0.001) (Figure 1). In psychiatric   evaluation, three out of 
four patients (75%) had BED and one (25%) had ED-NOS in Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Group 1. Two out of three patients (67%) had BED, and one 
(33%) had ED-NOS. No patients had AN or BN.
When the relationship between EDs and depression/anxi-
ety scores was considered, mean BAI scores of the patients 
with an ED were higher than those without an ED, and the 
statistical difference was significant (P = 0.004) (Table 2). 
In addition, when the presence of anxiety is considered, the 
difference between the patients with an ED and those without 
an ED was statistically significant (P = 0.002). BDI did not 
show any correlation with ED scores; thus, the existence of 
depression was not related to an ED.
The relationship between PASI and other parameters 
(criteria of MBS, anxiety, and depression) was evaluated 
statistically. Only the presence of depression revealed a 
significant difference (P = 0.031).
Discussion
Psoriasis is a chronic, immunologically based, inflamma-
tory disease associated with many comorbidities related to 
immune-mediated inflammation and metabolic dysregulation. 
In particular, recent studies have focused on the MBS and 
its components such as atherogenesis, hypertension, and 
insulin resistance. It is hypothesized that proinflammatory 
cytokines and pathomechanisms in inflammation are shared 
in both psoriasis and MBS.1,4 In fact, this association alone 
was proven; it was not considered a causality. Hence, a new 
problem has emerged with additional risk factors such as 
cigarette smoking, excessive alcohol consumption, and obe-
sity, which predispose psoriatic patients to develop MBS.4,14–16 
This hypothesis was reinforced by Alsufyani et al.4 They sug-
gested that speculation exists as to whether this association 
is causative or whether it is the result of other habits seen in 
psoriasis patients, such as increased rates of smoking, alcohol 
consumption, and sedentary lifestyle, which add to the com-
plexity of the association between psoriasis and MBS.
Some authors proposed that abnormal eating behavior 
associated with a sedentary lifestyle may contribute to the 
development of obesity.14 This was previously demonstrated 
in some studies, in particular for BED, short-term overeat-
ing, and ED-NOS.30–32 BED is characterized by recurrent 
episodes of binge eating. In fact, binge eating behaviour 
which is also seen in many cases of AN and BN is the main 
characteristic of ED. Although little is known about MBS 
in obese patients with BED, laboratory studies have shown 
that eating behaviors frequently found in BED patients may 
increase the risk of metabolic abnormalities. For example, 
in one study, increased eating rate has been demonstrated to 
be associated with central obesity, elevated serum lipids, and 
fatty liver.32 The results of a longitudinal study conducted 
by Hudson et al showed that BED may increase the risk 
of components of MBS independent of the risk conferred 
by obesity alone.18 Interestingly, metabolic abnormalities 
have even been observed in healthy lean women following 
laboratory-based binge-like episodes.33 The fact that the mean 
ED score was higher in psoriatic patients with MBS than 
in those without MBS is in accordance with literature data 
implicating a link between MBS and ED.32,34 However, the 
Table  1  Demographic  and  clinical  characteristics  of  psoriatic 
patients with MBs and without MBs
Patients  
with MBS  
(n = 31)
Patients  
without MBS  
(n = 69)
P
sex, male/female 17/14 38/31 0.983
Age, mean ± sD 48.55 ± 13.46 37.78 ± 16.03 0.002
Disease duration,  
mean ± sD
13.72 ± 10.65 10.18 ± 9.54 0.101
PAsI, mean ± sD 13.92 ± 11.01 16.52 ± 12.32 0.327
PAsI . 10, n (%) 17 (54.8) 36 (52.2) 0.851
Type of psoriasis, n (%) 
Type 1 
Type 2
 
20 (64.5) 
11 (35.5)
 
54 (78.3) 
15 (21.7)
0.147
Abbreviations:  MBs,  metabolic  syndrome;  PAsI,  psoriasis  area  severity  index;   
sD, standard deviation.
17.9
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Eating attitudes test-40 mean score
Patients with MBS  
Patients without MBS  
Figure 1 Mean scores of eAT in patients with MBs and patients without MBs 
(eAT = 17.900 ± 9.558 and 11.500 ± 7.204, P , 0.001).
Abbreviations: eAT, eating attitudes test; MBs, metabolic syndrome.
Table  2  Beck  anxiety  and  Beck  depression  mean  scores  in 
psoriatic  patients  with  eDs  and  without  eDs  (Mann–Whitney 
U-test; 95% confidence interval)
Eating attitudes test-40 P
.30 ,30
Mean ± SD Mean ± SD
Age 37.71 ± 9.55 41.38 ± 16.40 0.695
PAsI 14.70 ± 8.08 15.77 ± 12.17 0.945
Disease duration, years   7.50 ± 4.75 11.56 ± 10.22 0.457
Beck anxiety score (mean) 21.86 ± 6.09 11.92 ± 8.07 0.004
Beck depression  
score (mean)
18.14 ± 13.36 13.76 ± 12.01 0.295
Abbreviations:  eD,  eating  disorder;  PAsI,  psoriasis  area  severity  index;  sD, 
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number of patients was inadequate for statistical comparison 
for EDs. This may be a limitation of this present study. More 
reliable or indicative results are likely with a larger number 
of psoriasis patients. When considering the prevalence of 
EDs, there are different studies in different populations. 
Women, children, adolescents, and the obese have been the 
principal subjects for prevalence studies.32,35–37 In a large-
scale prevalence study including six European countries, AN 
0.48%, BN 0.51%, and BED 1.12% were found.38 Therefore, 
working with larger numbers of patients would probably be 
more indicative because of the small percentage of real EDs 
in the general population.
These data raise another question as to why psoriatic 
patients have EDs. The explanation comes from increased 
psychiatric comorbidity, in particular depression and anxiety, 
in psoriatic patients.14,15 There are some reports that indicate 
a link between ED and stress factors including anxiety and 
depression.20–22,35 This means that, in particular, anxiety 
associated with psoriasis may cause abnormal eating habits 
and resultant MBS in psoriasis. In a study conducted by   Herron 
et al obesity was suggested as a consequence of   psoriasis and 
not a risk factor for onset of disease.14 Accordingly, the authors 
of this present paper suggest that the interaction between 
psoriasis, psychiatric symptoms, and EDs may lead to obesity 
or MBS over time; that these current results showed higher 
mean age in MBS may reinforce this speculation.
According to this study’s findings, clinical severity of 
psoriasis measured by PASI seems to be an independent vari-
able in the relationship between EDs, MBS, and anxiety.
Conclusion
In conclusion, it appears that it is not adequate to establish 
the presence of comorbidities alone; defining risk factors 
leading to comorbidities is also important in patients with 
psoriasis. If causative factors are detected, controlling them 
by a multidisciplinary approach will prevent the onset of 
comorbidities and also provide both cost-effective and sat-
isfactory management of psoriasis.
Disclosure
The authors report no conflicts of interest in this work.
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